Cargando…

A Systems Pharmacology Model of Erythropoiesis in Mice Induced by Small Molecule Inhibitor of Prolyl Hydroxylase Enzymes

Mammalian erythropoiesis is a conserved process tightly controlled by the hypoxia-inducible factor (HIF1) pathway. In this study, a small molecule inhibitor (PHI-1) of prolyl-hydroxylase-2 (PHD2) enzyme involved in regulating HIF1α levels was orally administered to male BALB/c mice at 10 and 30 mg/k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, I, Nagiec, EE, Thompson, JM, Krzyzanski, W, Singh, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360669/ https://www.ncbi.nlm.nih.gov/pubmed/26225228 http://dx.doi.org/10.1002/psp4.12

Ejemplares similares

Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism
por: Yang, Ming, et al.
Publicado: (2014)

Prolyl 4 Hydroxylase: A Critical Target in the Pathophysiology of Diseases
por: Kant, Ravi, et al.
Publicado: (2013)

Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor
por: Wang, Ruth X., et al.
Publicado: (2021)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
por: Ogawa, Chie, et al.
Publicado: (2023)

Small-molecules that covalently react with a human prolyl hydroxylase – towards activity modulation and substrate capture
por: Bush, Jacob T., et al.
Publicado: (2019)

HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
por: Poloznikov, Andrey A., et al.
Publicado: (2021)

Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials
por: Yeh, Tzu-Lan, et al.
Publicado: (2017)

A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats
por: Signore, Pierre E., et al.
Publicado: (2021)

Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors
por: Holt-Martyn, James P., et al.
Publicado: (2019)

Hypoxia-inducible factor prolyl hydroxylase inhibitors in kidney transplant recipients
por: Ogata, Masatomo, et al.
Publicado: (2022)

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
por: Joharapurkar, Amit A., et al.
Publicado: (2022)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
por: Zheng, Li, et al.
Publicado: (2022)

Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer
por: Seeley, Todd W, et al.
Publicado: (2017)

Changes in Metabolomic Profiles Induced by Switching from an Erythropoiesis-Stimulating Agent to a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor in Hemodialysis Patients: A Pilot Study
por: Watanabe, Kimio, et al.
Publicado: (2023)

Discovery of Molidustat (BAY 85‐3934): A Small‐Molecule Oral HIF‐Prolyl Hydroxylase (HIF‐PH) Inhibitor for the Treatment of Renal Anemia
por: Beck, Hartmut, et al.
Publicado: (2018)

Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges
por: Harnoss, Jonathan Michael, et al.
Publicado: (2015)

The role of HIF prolyl hydroxylases in tumour growth
por: Jokilehto, Terhi, et al.
Publicado: (2010)

Function and expression of prolyl hydroxylase 3 in cancers
por: Liu, Qiu-long, et al.
Publicado: (2013)

Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor
por: Kiriakidis, Serafim, et al.
Publicado: (2017)

Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents
por: Yan, X, et al.
Publicado: (2013)

Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis
por: Zheng, Qiyan, et al.
Publicado: (2023)

HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review
por: Hirota, Kiichi
Publicado: (2021)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
por: Li, Jing, et al.
Publicado: (2022)

Structure–Activity Relationships and Transcriptomic Analysis of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
por: Poloznikov, Andrey A., et al.
Publicado: (2022)

Selective Inhibitors of a Human Prolyl Hydroxylase (OGFOD1) Involved in Ribosomal Decoding
por: Thinnes, Cyrille C., et al.
Publicado: (2019)

Effect of conjugated linoleic acid on inhibition of prolyl hydroxylase 1 in hearts of mice
por: Zhang, Jize, et al.
Publicado: (2012)

The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma
por: Hatzimichael, E, et al.
Publicado: (2012)

Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis
por: Yang, Junlan, et al.
Publicado: (2023)

Structure and Mechanism of a Viral Collagen Prolyl Hydroxylase
por: Longbotham, James E., et al.
Publicado: (2015)

Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat
por: Figg, William D., et al.
Publicado: (2021)

Role of prolyl hydroxylase domain proteins in bone metabolism
por: Wolf, David, et al.
Publicado: (2022)

A Novel Prolyl Hydroxylase Inhibitor Protects Against Cell Death After Hypoxia
por: Kontani, Satoru, et al.
Publicado: (2013)

Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications
por: Kim, So Yeon, et al.
Publicado: (2015)

Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases
por: Miao, Mengqiu, et al.
Publicado: (2022)

Cloning of the Human MORG1 Promoter: Differential Regulation by Hypoxia and Prolyl-Hydroxylase Inhibitors
por: Bondeva, Tzvetanka, et al.
Publicado: (2022)

Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2022)

Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
por: Chou, Yu-Hsiang, et al.
Publicado: (2023)

Structure‐Activity Relationship and Crystallographic Studies on 4‐Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors
por: Holt‐Martyn, James P., et al.
Publicado: (2019)

Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors induce autophagy and have a protective effect in an in-vitro ischaemia model
por: Singh, Ayesha, et al.
Publicado: (2020)

Prolyl-hydroxylase 3: evolving roles for an ancient signaling protein
por: Place, Trenton L, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1kjaami8gttq15udu5m5n0l2up